Phase 2b RCT | Efficacy and safety of Bepirovirsen in chronic Hepatitis B infection.
11 Nov, 2022 | 13:44h | UTCEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hep B virus (HBV) messenger RNAs, resulted in sustained loss of hep B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection. #TLM22 #LiverTwitter https://t.co/krJcMEDhIX pic.twitter.com/SistuAocZO
— NEJM (@NEJM) November 8, 2022